Neonatal exposure to anti-nerve growth factor antibodies affects exploratory behavior of developing mice in the hole board.
The aim of this study was to assess in developing mice whether the neutralization of endogenous NGF following ICV administration of anti-NGF antibodies (50 micrograms/2 microliters) on postnatal days 3, 6, 9, and 12 affected locomotor activity, exploratory behavior, and response to the cholinergic blocker scopolamine. In Experiments 1 and 2 activity and age-typical scopolamine effects were evaluated on PND 13 or 17 in an automated apparatus. No significant main effect of anti-NGF treatment was found at either age. On day 13 scopolamine (0.2, 1, or 2 mg/kg) decreased locomotion in both anti-NGF and control animals. In Experiment 3, locomotion and exploratory behavior were analyzed in an open field arena or in a hole board apparatus on PND 16. No significant effects of anti-NGF treatment on general motor activity and investigation of a novel object in the open field was found, though anti-NGF animals tended to be less active than controls. In the hole board anti-NGF pups showed a different pattern of head dipping behavior from controls, exploring mainly the holes located in the periphery of the apparatus.
Calamandrei
G
G
Laboratorio di Fisiopatologia O. S., Istituto Superiore di Sanità, Roma, Italy.
Pennazza
S
S
Ricceri
L
L
Valanzano
A
A
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology*; D000906:Antibodies / Q000008:administration & dosage / Q000502:physiology*; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology*; D005260:Female; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009414:Nerve Growth Factors / Q000502:physiology*; D012601:Scopolamine / Q000494:pharmacology
D000906:Antibodies; D009414:Nerve Growth Factors; D012601:Scopolamine